中国卫生产业
中國衛生產業
중국위생산업
CHINA HEALTH INDUSTRY
2012年
34期
20-21
,共2页
利妥昔单抗%CHOP方案%弥漫大B细胞性淋巴瘤%临床效果
利妥昔單抗%CHOP方案%瀰漫大B細胞性淋巴瘤%臨床效果
리타석단항%CHOP방안%미만대B세포성림파류%림상효과
Rituximab%CHOP program%Diffuse large B-cell lymphoma%Clinical effect
目的探讨分析利妥昔单抗联合CHOP方案治疗弥漫大B细胞性淋巴瘤的临床效果.方法?选取该院住院治疗的弥漫大B细胞性淋巴瘤患者86例随机分成两组,其中给予利妥昔单抗与CHOP方案联合治疗的49例患者为实验组,剩下的37例仅用单纯的CHOP方案化疗的患者为对照组,两组患者在接受6个疗程的治疗后,对比两组的临床治疗效果.结果?对照组有效率为86.49%,实验组有效率达到93.88%,明显高于对照组(P<0.05).结论?利妥昔单抗与CHOP方案联合治疗弥漫大B细胞性淋巴瘤临床效果显著,值得临床上进一步推广应用.
目的探討分析利妥昔單抗聯閤CHOP方案治療瀰漫大B細胞性淋巴瘤的臨床效果.方法?選取該院住院治療的瀰漫大B細胞性淋巴瘤患者86例隨機分成兩組,其中給予利妥昔單抗與CHOP方案聯閤治療的49例患者為實驗組,剩下的37例僅用單純的CHOP方案化療的患者為對照組,兩組患者在接受6箇療程的治療後,對比兩組的臨床治療效果.結果?對照組有效率為86.49%,實驗組有效率達到93.88%,明顯高于對照組(P<0.05).結論?利妥昔單抗與CHOP方案聯閤治療瀰漫大B細胞性淋巴瘤臨床效果顯著,值得臨床上進一步推廣應用.
목적탐토분석리타석단항연합CHOP방안치료미만대B세포성림파류적림상효과.방법?선취해원주원치료적미만대B세포성림파류환자86례수궤분성량조,기중급여리타석단항여CHOP방안연합치료적49례환자위실험조,잉하적37례부용단순적CHOP방안화료적환자위대조조,량조환자재접수6개료정적치료후,대비량조적림상치료효과.결과?대조조유효솔위86.49%,실험조유효솔체도93.88%,명현고우대조조(P<0.05).결론?리타석단항여CHOP방안연합치료미만대B세포성림파류림상효과현저,치득림상상진일보추엄응용.
Objective To investigate and analyse rituximab combination with CHOP in patients with diffuse large B-cell lymphoma clinical effect. Method Select 86 cases of diffuse large B-cell lymphoma patients treatment in our hospital,randomly divided into two groups,which given rituximab with CHOP regimen combined treatment of 49 patients for the experimental group,and the remaining 37 cases only pure CHOP chemotherapy patients as the control group,the two groups of patients received six courses of treatment, the clinical effect of the two groups were compared. Results The control group efficiency was 86.49%,the experimental group efficiency of 93.88%,significantly higher than the control group(P <0.05). Conclusion Rituximab and CHOP regimen combined treatment of diffuse large B-cell lymphoma significant clinical effect,it is worth further promote in the use of clinical.
